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ABSTRACT

IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS: A REVIEW AND A PROPOSED ROLE
FOR PATIENT-REPORTED OUTCOMES.
Conor W. Grady (Sponsored by Charles C. Matouk). Department of Neurosurgery, Yale University,
School of Medicine, New Haven, CT.

Despite nearly five decades of experience treating idiopathic normal pressure hydrocephalus (iNPH),
there is still no consensus amongst care providers as to how to reliably identify patients with suspected
iNPH who will benefit from shunt surgery, or how to measure post-operative symptom improvement. We
performed a selective review of the literature, focusing especially on the role of neuroimaging in aiding in
the diagnosis of iNPH, and the various clinical scales that have historically been used to assess outcome.
Further, we tested the hypothesis that patient-reported outcomes (PROs) will demonstrate effectiveness of
shunt surgery for the relief of iNPH symptoms consistent with that demonstrated through the application
of clinical scales. To do this, we performed a retrospective analysis of one provider’s experience treating
patients with suspected iNPH, scoring outcomes based on patient-reported change in symptom severity.
All patients treated for suspected iNPH between January 2012 and January 2014 with at least one month
of follow-up and documented responses to direct questioning about pre- versus post-surgical symptom
severity were included. Twenty-one patients were included in total. 100% of patients reported
improvement in at least one of the three cardinal symptoms of gait disturbance, urinary incontinence, or
cognitive impairment following shunt implantation. Gait, urinary, and cognitive symptoms individually
improved 95%, 84%, and 89%, respectively. There was a significantly higher rate of improvement in any
(i.e. at least one) symptom domain using PROs compared to historical data obtained through evaluation
with clinical scales. There was no statistically significant difference between improvements in each
individual symptom domain. PROs produce results that are largely consistent with data obtained by
clinical scales, and can be used as one metric of patient improvement following shunt surgery for iNPH.
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Introduction
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Normal pressure hydrocephalus (NPH) was first described in the English clinical
literature in 1965 as a syndrome characterized by gait disturbances, cognitive
impairment, and urinary incontinence in the setting of ventriculomegaly and normal
opening pressure on lumbar puncture (1,2). Standard treatment for the disorder is the
surgical diversion of CSF though the implantation of a shunt. Early clinical series
reported questionable outcomes and high complication rates in shunt surgery for patients
with NPH (3,4); in the decades that have followed, numerous studies have attempted to
predict which patients will respond to shunting, leading to a proliferation of clinical
scoring systems and proposed treatment algorithms (4-8).

NPH is categorized as either secondary or idiopathic. Secondary NPH has an identifiable
etiology, such as subarachnoid hemorrhage or meningitis, while the etiology of idiopathic
NPH remains unknown. The diagnosis of idiopathic NPH (iNPH) is complicated by the
similarity of its clinical presentation to that of other neurological diseases typically
affecting patients over 65, including Alzheimer’s dementia and Parkinson’s disease,
which do not respond to CSF diversion procedures (9). Because of this, current
guidelines recommend the categorization of patients into “probable”, “possible”, or
“unlikely” iNPH based on clinical and radiological findings that have been associated
with positive response to shunting (10,13). The diagnosis of iNPH is definitely made by
improvement of the patient’s symptoms following shunt surgery (13).

Despite the diversity of inclusion criteria and metrics for evaluating outcomes used by
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different studies, recent systematic reviews indicate that more than 70% of patients who
receive a shunt for the treatment of iNPH will experience lasting improvement of at least
one of their symptoms (14). As such, though little is known about its pathophysiology
and no high quality studies have assessed the efficacy of shunting versus conservative
management (15), there is evidence that iNPH is a clinical entity with an effective
treatment.

In this thesis, I present a review of the current literature on iNPH, with an emphasis on
the role of neuroimaging, patient outcomes, and the various outcome measures used. We
additionally include an analysis of the experience in treating iNPH at Yale-New Haven
Hostpial, examining outcomes assessed by patient-reported primary end-points. The
primary goal of this analysis was to investigate whether, in the absence of consensus
means of evaluating outcomes in iNPH, using patient-reported endpoints will lead to a
significantly different rate of response compared to the most recent rates reported in the
literature. The secondary goal of this analysis was to examine if there are any patient
characteristics that correlate with response to shunting for iNPH as assessed by patientreported end-points.

Review of the Literature
Methods
The review presented in this thesis is based on a selective review of the literature,
including the most recent English-language guidelines (10-13), select review articles
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published since 2001, and original literature retrieved by a search of PubMed. As there is
no level 1 data on the treatment or diagnosis of NPH, all clinical data summarized are
level 2 or 3. Level of evidence is determined using the system established in the most
recent international guidelines (15).

Epidemiology
Little is known about the prevalence and incidence of iNPH, as reported figures vary
widely. A door-to-door survey of 982 individuals older than 65 resulted in a reported
prevalence of 0.41% (17). Examining neurosurgical referrals in a stable Norwegian
population, prevalence appeared to be highly age dependent, ranging from 3/100,000 in
those aged 50-59 to 181.7/100,000 in those 70-79 (18). This same study reported an
overall incidence of 5.5/100,000. A random sampling of a Japanese population aged 65
years or older found the prevalence of iNPH to be 1.4% as diagnosed by
ventriculomegaly on neuroimaging and at least one element of the classical clinical triad
of gait disturbance, cognitive impairment, or urinary incontinence (19). In a population of
assisted-living and extended-care facility residents, incidence ranged from 9% to 14%
(20). All of these studies acknowledged that their findings were highly dependent on the
diagnostic criteria used.

Another important consideration in the epidemiology of iNPH is its rate of comorbidity
with other neurologic disease. In a study of 28 patients with iNPH diagnosed by clinical,
radiological, and CSF dynamic criteria, 89% had pathologic findings consistent with
some neurologic disease, and 78% had evidence of Alzheimer’s disease, cerebrovascular

disease, or both (21). Others have reported biopsy-confirmed Alzheimer’s disease in as

4

many as 75% of patients undergoing shunt placement for treatment of iNPH (22). Such
data are significant, as it has been hypothesized that patients with dementia not entirely
attributable to iNPH may still experience resolution of gait and urinary symptoms
following shunting (23).

Pathophysiology
The exact pathophysiological mechanism by which iNPH arises is unknown. The most
common pathological findings in iNPH are evidence of Alzheimer’s disease and
cerebrovascular disease; there are no pathologic findings specific to iNPH (13).
Numerous etiologies have been proposed for iNPH, with the majority attributing the
disease to a combination of periventricular ischemia and disturbed CSF fluid dynamics
(24). Current hypotheses include mechanical compression of the brain parenchyma by
dilated ventricles, accumulation of toxic metabolic products as a result of decreased CSF
turnover, and periventricular microvascular damage caused by increased arterial
pulsations (25).

Diagnosis
Since its discovery, multiple criteria have been proposed for the diagnosis of NPH,
ranging from positive response to shunt placement (26) to the presence of only one of the
classic triad of symptoms with radiologic confirmation of communicating hydrocephalus
(27). Because of the absence of a consensus set of diagnostic criteria, a considerable
amount of research has been devoted to determining which patients are most likely to

respond to shunting (4-8). The information provided by these studies has been
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synthesized into international guidelines, which recommend that patients be diagnosed
with “probable”, “possible”, or “unlikely” hydrocephalus based on a combination of
clinical and radiological findings associated with positive response to shunt placement
(10,13). One set of guidelines still reserves a definitive diagnosis of iNPH for those who
show improvement of symptoms with shunting (13).

Clinical Features
The full syndrome of gait disturbance, cognitive impairment, and urinary incontinence
may be present in as few as 51% of patients with probable iNPH (28). At least one
component of the triad, however, is essential to the diagnosis of the disease.

Gait impairment is the most common presenting symptom, though it may be subtle early
in the course of the disease. The gait disturbance seen in iNPH is characterized by
imbalance, short steps, broad stance, difficulty turning, and outward rotation of the feet. It
does not improve with visual or auditory cues, unlike a Parkinsonian gait. Apraxia is
rarely a component of the gait disturbance typical of iNPH (29). Depending on the
precise diagnostic criteria applied, between 94% and 100% of patients with iNPH will
have gait disturbances (13). Both sets of English-language guidelines have prominent gait
disturbance as an essential feature of probable iNPH (10,13).

The cognitive dysfunction seen in iNPH is typically frontal-subcortical in nature. Its most
prominent features are impaired executive function, impaired concentration and attention,

psychomotor slowing, and impaired working memory (23,30). Recall memory is
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typically preserved. Features of cortical dementia such as gross amnesia, disorientation,
and aphasia are decreased relative to the cognitive impairment typical of Alzheimer’s
disease (30). Cognitive impairment is seen in 78% to 98% of patients with iNPH (13).

The urinary symptoms of iNPH range from increased urinary frequency to gross
incontinence. The underlying cause of the urinary symptoms is detrusor hyperactivity
resulting from a reduction of central inhibitory control (31). Patients typically progress
from increased frequency, to urge incontinence, and finally to frank urinary incontinence.
Of note, bowel incontinence is extremely rare in iNPH, and is likely indicative of
progressive frontal lobe dysfunction rather than further loss of central control over
sphincter function (23).

Average CSF opening pressure in patients with iNPH is mildly elevated relative to
healthy individuals (32), but by definition must be below either 18cm H2O or 20cm H2O,
depending on the diagnostic criteria used (10,13).

In the patient’s history, age greater than 65, insidious onset, and progression of symptoms
are consistent with a diagnosis of iNPH (10). An identifiable etiology of the
hydrocephalus excludes a diagnosis of iNPH.

The Role of Neuroimaging
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Radiologic evidence of hydrocephalus is essential to the diagnosis of iNPH.
Traditionally, an Evans index (33) greater than 0.3 on CT or MRI has been the standard
for the diagnosis of ventricular enlargement (10). This, in combination with the absence
of evidence of CSF flow obstruction, constitutes the minimum radiologic indication of
iNPH. Beyond this, however, there is considerable debate as to what other neuroimaging
findings might be of use in the diagnosis and evaluation of iNPH. In the sections that
follow, I will discuss ways in which various imaging modalities have been used to assess
patients with suspected iNPH and assess their role in clinical practice.

Anatomic and Volumetric Studies
Since the advent of modern neuroimaging, numerous studies have attempted to identify
anatomical and volumetric findings on conventional CT and MRI that could serve as
diagnostic or prognostic markers for iNPH. One of the earliest such studies, by Borgsen
and Gjerris (34), interrogated the possible connection between the degree of ventricular
dilation as measured by the Evans index, the size of cortical sulci, and the presence or
absence of periventricular lucencies with outcome following shunting in patients with
suspected NPH. Sixty-four patients with either iNPH or secondary NPH who met the
criteria of 1) presenting with the full triad of cardinal symptoms 2) symptom duration of
greater than three months and 3) CT-confirmed ventriculomegaly were treated with
ventriculo-atrial shunts. Their outcomes were then correlated with their findings on CT.
Ventricular size was not significantly associated with outcome, but both small cortical

sulci and the presence of periventricular lucencies were identified as predictors of
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positive response to shunting (34).

In the decades since the publication of Borgsen’s and Gjerris’s work, the proliferation of
low-powered studies proposing radiologic findings with either diagnostic or prognostic
value in the evaluation of iNPH have resulted in an inconsistent body of literature. Some
findings, such as hippocampal atrophy, have been demonstrated in patients with iNPH
relative to healthy controls, but are also known radiologic features of other
neurodegenerative diseases, and are therefore of limited diagnostic significance (35).
Others, such as the periventricular lucencies identified by Borgsen and Gjerris, have
failed to consistently demonstrate their proposed utility as predictors of outcome (36,37).
Still others have been complicated by revision, such as the discovery that limited areas of
focal sulcal dilation in the setting of generally small cortical sulci could be observed in
patients ultimately diagnosed with shunt-responsive iNPH (38). As a result, though there
are many radiologic findings generally believed to be useful in the diagnosis or
evaluation of iNPH, there is presently no consensus to what extent or in what way these
findings should influence clinical practice.

Despite this, many recent studies continue to attempt to identify additional anatomical
and volumetric markers in suspected iNPH. A recently investigated anatomic marker is
the callosal angle, which is measured between the lateral ventricles in a coronal image
taken through the posterior commissure and oriented perpendicular to the anterior
commissure-posterior commissure plane. As a diagnostic aid, Ishii and colleagues
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demonstrated that patients with iNPH had significantly smaller callosal angles than either
patients with Alzheimer’s dementia or healthy controls (39). Using a cutoff of 90°, they
were able to distinguish iNPH from Alzheimer’s dementia with an accuracy, sensitivity,
and specificity of 93%, 97%, and 88%, respectively. When they added to this the
requirement of an Evans index of 0.3 or greater, their results improved to 96%, 97%, and
94% (39). Virhammar, et al., investigated the callosal angle as a predictor of outcome
following shunt surgery. Looking at 108 patients who received shunts for suspected
iNPH, they found that patients with shunt-responsive iNPH had significantly smaller
callosal angles than did patients whose symptoms did not respond to shunt surgery (59°
versus 68°). Using ROC analysis, they determined an optimal cutoff of 63°, resulting in a
sensitivity and specificity of 67% and 65%, respectively (40).

Volumetric analyses have likewise yielded a variety of results. With respect to predicting
surgical outcomes, one study of 26 patients with suspected iNPH failed to demonstrate
any significant difference in mean ventricular volume ratio, mean brain volume ratio,
mean pericerebral CSF volume ratio, or mean ventricular/pericerebral CSF volume ratio
between shunt-responders and non-responders (41). Looking at compartmental variations
in CSF volume, another group demonstrated that 11 patients with shunt-responsive iNPH
had increased CSF volume in the lateral ventricles and Sylvian fissures, but decreased
CSF volume in the superior convexity and medial subarachnoid spaces compared to
patients with Alzheimer’s dementia and age-matched, healthy controls (38). Building on
these findings, a multicenter, prospective study selected 100 patients for shunt surgery
based on clinical presentation consistent with iNPH and MRI findings of tight superior

convexity and medial subarachnoid spaces with enlarged Sylvian fissures and
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ventriculomegaly, a constellation of imaging findings collectively referred to as
Disproportionately Enlarged Subarachnoid-space Hydrocephalus (DESH). At one year
following surgery, 69% of patients demonstrated improvement of 1 point or more on the
modified Rankin Scale, and 89% had demonstrated improvement at some point during
the year (42).

In a prospective study of 43 patients with suspected iNPH, Lee and colleagues
simultaneously investigated the connection between many of the proposed anatomic and
volumetric markers of iNPH and response to CSF tap test. Frontal convexity narrowing,
parietal convexity narrowing, empty sella, upward bowing of the corpus callosum, and
narrowing of convexity with dilation of sylvian fissure CSF spaces (i.e. DESH) were all
compared against patient response to the removal of 40ccs of CSF via lumbar puncture.
Of these, both an empty sella and DESH were significantly linked to positive response to
CSF tap test, with the presence of either of the two signs corresponding to a sensitivity,
specificity, positive predictive value, and negative predictive value of 72.7, 81, 80, and
73.9%, respectively (43).

International guidelines have attempted to synthesize the literature on anatomic and
volumetric findings in iNPH. The 2005 guidelines authored by the NPH independent
study group listed callosal angle, temporal horn size, and periventricular lucencies as
radiologic findings worth assessing when considering a diagnosis of iNPH (10). More
recently, the updated guidelines of the Japanese Neurosurgical Society, published in
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English in 2012, did not list any anatomic findings, listing instead only those volumetric
findings consistent with DESH as radiologic findings indicative of iNPH (13).

Of note, though there are no anatomic or volumetric radiologic findings that can confirm
a diagnosis of iNPH or predict a patient’s response to shunting, several studies have
indicated that there are also no radiologic findings that should prevent a patient with
suspected iNPH from being considered for shunt implantation. Specifically, deep white
matter lesions representing hypertensive or lacunar infarcts are not predictive of a poor
response to shunting, and therefore should not rule out a diagnosis of iNPH (44,60).

Imaging of CSF Dynamics
Abnormal CSF dynamics are believed to contribute to the pathogenesis of iNPH (24). As
such, analysis of CSF flow using phase-contrast MRI has been investigated for potential
diagnostic and prognostic information in the assessment of patients with suspected iNPH.
Early studies were promising; a chart review of twenty patients, with eleven followed up
to five years after shunt surgery, showed a significant correlation between increased
aqueductal CSF flow void and good or excellent outcome (45). A later prospective study
by the same author, however, failed to recreate this finding, while identifying CSF stroke
volume through the cerebral aqueduct greater than 42μL as a predictor of shuntresponsiveness (46).

Subsequently, better-powered, better designed studies have failed to find significant
differences in either CSF flow void intensity or CSF stroke volume between either shunt
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responders and non-responders amongst patients with suspected iNPH, or between iNPH
patients and patients with other forms of dementia. In a prospective trial of 49 patients
shunted for suspected iNPH, CSF flow through the cerebral aqueduct did not

significantly correlate with clinical outcome (47). Another study comparing patients with
a clinical diagnosis of iNPH to patients with early Alzheimer’s dementia, patients with
early vascular dementia, and healthy controls found that there was no difference in
aqueductal stroke volume between the groups (48).

More recent studies have continued to interrogate CSF stroke volume, while also
investigating additional CSF dynamic parameters. In a retrospective study, Forner-Giner
and colleagues stated that increased average CSF flow of 18.2mL/min and increased
mean CSF stroke volume of 138.7μL were both 100% specific and 86% and 79%
sensitive, respectively, at correctly identifying patients with shunt-responsive iNPH from
patients with ischemic cerebrovascular disease (ICD) or healthy controls (49). It should
be noted, though, that the cohorts in this study were unequal (61 healthy, 19 ICD, 24
NPH) and were not age-matched.

The diverse and occasionally contradictory nature of the results of these studies has been
hypothesized to be the result of a high degree of variability in technique in image
acquisition and data analysis between institutions (50). As such, both the diagnostic and
prognostic value of phase-contrast MRI measurements of CSF fluid dynamics in the
evaluation of patients with suspected iNPH is highly uncertain at present.

Functional Neuroimaging
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Functional imaging modalities measuring blood flow and metabolism can provide insight
into regional patterns of activity or dysfunction within the brain. As abnormal cerebral
blood flow (CBF) is thought to contribute to the pathogenesis of iNPH, a number of
different types of functional imaging have been investigated for possible utility in the
assessment of patients with iNPH. Below, we will discuss these various imaging methods
and evaluate their role in guiding clinical decision making.

Positron Emission Tomography (PET)
One of the earliest studies examining the potential role of functional imaging in the
treatment of iNPH investigated whether or not iNPH could be distinguished from
Alzheimer’s dementia based on patterns of cortical metabolism. Three patients with
NPH, seventeen with Alzheimer’s disease, and seven age-matched controls were
compared to one another on the basis of fluorine-18-labeled fluorodeoxyglucose (18FFDG) utilization. Both the iNPH and Alzheimer’s groups showed reduced cortical
metabolism relative to controls. The pattern of hypometabolism differed between the two
groups, however; Alzheimer’s patients demonstrated a pattern of bitemporal
hypometabolism, while NPH patients showed a global reduction in cortical glucose use
(51).

Subsequently, Momjian, Owler, and colleagues expanded on these findings by using 15OH2O PET to identify the thalami, basal ganglia, and periventricular regions as areas of
decreased CBF in patients with iNPH relative to healthy controls (52,53). Klinge and

14

colleagues also demonstrated a correlation between decreased regional CBF in the medial
frontal lobes and anterior medial temporal lobes as measured by 15O-H2O PET, and presurgical symptom severity in patients with a clinical diagnosis of iNPH. In this same
study, they also showed a significant difference between shunt responders and nonresponders with respect to increased medial frontal lobe CBF following shunt surgery,
though there was no significant difference in regional CBF between these two groups’
pre-operative studies (54).

Calcagni, et al., recently performed a prospective study of the change in regional cerebral
metabolic rate of glucose (CMRglu), as measured by 18F-FDG utilization, following
shunt surgery in 20 patients with clinically diagnosed iNPH. Following shunting, the 17
patients who improved demonstrated globally increased CMRglu relative to their presurgical studies. In contrast, the three non-responders only showed increased CMRglu in
the left frontal cortex, left putamen, and right thalamus, respectively. Notably, there was
no difference in CMRglu between shunt responders and non-responders on pre-operative
exam. There was, however, a statistically significant correlation between the magnitude
of increase in CMRglu and degree of clinical improvement between individual shuntresponders’ pre- and post-operative studies (55).

Though numerous studies have demonstrated post-operative changes in patterns of
cerebral metabolism and blood flow, no studies to date have found any ability of PET to
predict clinical outcome following shunt surgery in patients with suspected iNPH.
Additionally, studies demonstrating findings of potentially diagnostic regional
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hypometabolism or hypoperfusion have used small cohorts. Though studies utilizing PET
offer a promising glimpse into possible mechanisms of pathogenesis in iNPH, they have
done little to establish PET’s clinical utility.

Single-Photon Emission CT (SPECT)
Early studies attempting to correlate patterns of regional CBF visualized by SPECT with
diagnosis or outcome following shunting in patients with suspected iNPH offered
promising results. In a study of 22 patients who received shunts following a clinical
diagnosis of iNPH, Graff-Radford and colleagues found that an anterior/posterior CBF
ratio cutoff of 1.05 was able to correctly classify the outcome in 19 of the cases; all but
one of the patients who did not respond to shunting had anterior/posterior CBF above
1.05, while all but two of the patients who responded to shunting had ratios below this
threshold (56). This same group subsequently recreated these findings, showing that
increased anterior/posterior CBF ration correlated with increased likelihood of a nonresponse to shunting in patients with suspected iNPH (57).

In a study of 37 patients with suspected iNPH, Chang, et al., demonstrated decreased
mean CBF relative to age-matched healthy controls. This same study showed that
patients who responded to shunting, while still possessing lower mean CBF than controls,
had higher CBF than patients with suspected iNPH who did not respond to shunting (58).

More recent studies have failed to reproduce these promising initial results. A study of 84
patients with iNPH as diagnosed by DESH criteria found three patterns of reduced
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regional CBF relative to healthy controls. Specifically, 58% of patients showed anteriordominant reduction in CBF, 12% showed posterior-dominant reduction, and 30% had

mixed or diffuse-type reduction. Though the finding of predominantly anterior reduction
in CBF in the majority of patients would seem to support the earlier finding of a
relatively lower anterior/posterior CBF ratio in shunt-responders, there was no significant
difference in responsiveness to shunting between the three types, which responded at
rates of 83, 90, and 84%, respectively (59). A similar pattern and patient distribution of
anterior-, posterior- and mixed-type reduced CBF was seen in a more recent study, which
also showed no link between the pattern of reduced CBF and outcome (60).

While SPECT has consistently demonstrated patterns of reduced CBF in patients with
suspected iNPH relative to healthy individuals, the largest and most recent studies
investigating the utility of the modality as a prognostic or diagnostic tool have failed to
show a significant link between SPECT findings and patient outcome.

Dynamic Susceptibility Contrast MRI
Relatively few studies have attempted to use MR perfusion studies to identify diagnostic
or prognostic markers of use in the assessment of patients with suspected iNPH. The
largest and most recent of these was a prospective study conducted by Zieglitz, et al., in
which dynamic susceptibility contrast MRI findings in user-selected regions-of-interest
were compared in 21 patients with the clinical diagnosis of iNPH and 16 age-matched
healthy controls. All members of the iNPH cohort were then shunted, and pre- and postoperative imaging studies of shunt responders and non-responders were compared.
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Patients with iNPH demonstrated significantly reduced regional CBF in the basal medial
frontal cortex, the hippocampus, the lentiform nuclei, and all regions of the
periventricular white matter compared to healthy controls. With respect to outcomes,
shunt responders demonstrated a greater reduction in CBF of the periventricular white
matter compared to non-responders, which fit with the additional finding that the
magnitude of reduction of CBF to the periventricular white matter seen on pre-operative
studies was directly correlated with symptom severity, and patients with worse
symptomatology at the time of shunting received more obvious benefit from CSF

diversion. Non-responders had reduced CBF of the basal medial frontal cortex relative to
shunt responders (61).

Further study is needed to establish the clinical role for MR perfusion studies in the
assessment or management of iNPH. Presently, however, it is a modality that potentially
offers insight into the pathogenesis of iNPH while further elucidating the findings of
other functional imaging studies.

Functional Imaging: Conclusion
In a 2001 review, Owler and Packard noted that measures of CBF had failed to improve
either the diagnostic or prognostic accuracy of the assessment of patients with suspected
iNPH, largely due to center-specific technical and methodological differences (62). More
than a decade later, this is still the case. Though functional imaging continues to be a
valuable research tool, there are presently no diagnostic or prognostic markers of reliable
clinical utility.
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Diffusion MRI
The clinical utility of diffusion MRI has been the focus of a number of studies in recent
years. Studies attempting to identify diagnostic markers by diffusion tensor imaging
(DTI) have produced especially consistent results. Kim and colleagues looked at
differences between 16 patients with shunt-responsive iNPH relative to 10 patients with
Alzheimer’s dementia, 10 patients with vascular dementia, and 20 healthy controls using
region-of-interest-based DTI. The iNPH patients were found to have higher fractional
anisotropy (FA) in the posterior limb of the internal capsule (PLIC) relative to the all
other cohorts. Using ROC analysis to arrive at an optimal cutoff value of 0.613, the
authors were able to identify iNPH relative to either healthy controls or other dementia
patients with a sensitivity and specificity of 87.5% and 95.0%, respectively (63). Another
recent study used DTI to compare a cohort of 24 patients with a clinical diagnosis of
iNPH to 20 healthy controls, and also found significantly higher FA in the PLIC of iNPH
patients (64). This study found a considerably more significant decrease in FA in the
corpus callosum of iNPH patients relative to healthy controls, however, and was able to
correlate lower FA in the corpus callosum with worse gait symptomatology at
presentation. Both of these studies support an earlier finding by Hattingen, et al., that
patients with iNPH have higher FA in the periventricular corticospinal tract, and lower
FA in the corpus callosum (65).
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Aside from these findings, other diagnostic markers of iNPH on DTI have been proposed,
including fornix length (66) and specific patterns of intracranial mean diffusivity (67),
but these have yet to be reproduced by other studies.

Previous studies have reported that patients with NPH had increased apparent diffusion
coefficient (ADC) in the periventricular white matter (68). In a study of 11 patients with a
clinical diagnosis of iNPH, Corkill, et al., investigated the ability of periventricular white
matter ADC to predict patients response to shunting. Patients who did not improve with
shunting were found to have significantly higher periventricular white matter ADC when
compared both to shunt-responsive iNPH patients and age-matched healthy controls (69).
More recently, it has been demonstrated that increased changes in ADC with each cardiac
cycle can be of use in distinguishing iNPH from both healthy controls and patients with
Alzheimer’s and Parkinson’s diseases (70,71).

Diffusion MRI may provide diagnostic markers, especially on DTI, though these findings
need to be validated in larger studies. The ability of diffusion MRI to predict patient
outcome to shunting in cases of suspected iNPH is difficult to assess given the limited
number of studies investigating the topic.

MR Spectroscopy
MR spectroscopy (MRS) enables investigators to search for distinguishing patterns of
regional metabolite concentration in the brains of patients with likely iNPH. One early
study attempting to differentiate various dementia syndromes from on the grounds of MR

spectroscopic data found that, of the syndromes investigated, only iNPH had potential
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marker on MRS (72). This marker, an increased lactate/creatinine ratio in intraventricular
CSF, was also identified in a small cohort study conducted by Kizu and colleagues (73).

More recent studies have investigated the relative concentrations of various metabolites
within the brain parenchyma. In a prospective study comparing 24 patients diagnosed
with iNPH on the grounds of clinical presentation, radiographic findings, and positive tap
test, 11 patients with other forms of dementia, and 20 healthy controls, both iNPH and
otherwise demented patients had decreased N-acetyl Acetate(NAA)/creatinine and
NAA/choline ratios in their white matter relative to the control group. No significant
difference was seen between the iNPH and other demented patients, and no significant
correlation was found between MRS findings and response to shunting within the iNPH
cohort (74). A similar finding was reported by Lundin, et al., who discovered decreased
NAA levels in the thalami of patients with a clinical diagnosis of iNPH compared to agematched healthy controls (75). It should be noted, however, that Lundin, et al. showed
decrease NAA in the thalami; there was no difference in NAA concentration between
iNPH patients and controls in any other regions examined, including those investigated
by the earlier study.

The clinical role of MRS is uncertain at this time. Though some patterns of metabolite
concentration in both CSF and brain parenchyma seem to correlate with a diagnosis of
iNPH, the studies demonstrating these are small, and their findings are not sufficiently
consistent across studies to allow any conclusions to be drawn.
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Neuroimaging – Conclusion
The role of various imaging modalities in the evaluation of patients with suspected iNPH
is an ongoing area of significant investigation. Presently, no single imaging modality can
provide clinicians with definitive diagnostic or prognostic information.

Treatment
The discovery of NPH was defined by improvement of patients’ dementia following the
diversion of CSF through the surgical placement of a shunt (2). Presently, shunt surgery
remains the mainstay of treatment for iNPH; some diagnostic criteria even require a
response of a patient’s symptoms following shunt placement for the diagnosis of
definitive iNPH to be made (13).

In the late 1990s, endoscopic third ventriculostomy (ETV) was proposed as an alternative
to shunt surgery for the treatment of iNPH (76). One multicenter study showed outcomes
equivalent to those seen in patients treated with shunt surgery, with 69% of patients
treated with ETV showing some improvement at 24 months after surgery (77).
Subsequent studies demonstrated similar outcomes, though improvement was most
significant in younger patients and in those with increased resistance to ventricular CSF
outflow (78,79).

Two recent studies have examined the relative safety and effectiveness of shunt surgery
and ETV in the treatment of iNPH. A robust, population-based study used a national
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database of the ICD-9 discharge codes for ETV and shunt surgery in patients diagnosed
with iNPH to investigate the perioperative mortality and complication rate for each

procedure. The findings showed ETV to have a perioperative mortality rate of 3.2% and a
complication rate of 17.9% compared to a mortality rate of 0.5% and a complication rate
of 11.8% in shunt surgery (80). Additionally, a randomized, parallel, open-label trial
showed superior outcomes in patients treated with shunt surgery versus those treated with
ETV; 76.9% of patients treated with shunt surgery showed some improvement 12 months
after their procedure compared to 50% of those who underwent ETV (81). These studies
indicate that shunt surgery is presently a safer and more effective treatment than ETV for
iNPH.

The role of conservative management in patients with suspected iNPH has not been well
characterized. There is currently a double-blind, randomized, controlled trial assessing
conservative management versus shunt surgery underway, but it has yet to announce any
findings (82). One systematic review of the literature showed that a small number of
patients with suspected iNPH may improve without surgical treatment, but that more than
half of patients showed measurable deterioration in at least one of their symptoms three
months after initial evaluation (83). A recent retrospective review compared serial preand post-operative exams of patients who had waited at least six months for shunt surgery
after receiving a clinical diagnosis of iNPH to similar exams of patients who had received
shunt surgery within three months of receiving their diagnosis. The delayed shunting
cohort experienced significant decline in all symptom categories accept for incontinence
in the months prior to their surgery, and their post-operative improvement, while

significantly improved over their last pre-operative exam, was significantly worse than
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the outcomes in the more rapidly shunted cohort (105).

Presently, shunt surgery remains the treatment of choice for patients with iNPH. Current
trials comparing conservative management to shunting will have the dual benefit of
revealing what role conservative management should play in the treatment of iNPH, as
well as providing level 1 data on shunt surgery’s effectiveness as a treatment for the
disorder. The limited data that is available indicates that earlier shunting in patients with
suspected iNPH may prevent further progression of the patients symptoms.

Outcomes – Challenges
The response of gait, urinary, and cognitive symptoms to shunt surgery has been central
to both the discovery and subsequent decades of diagnosis of NPH. Despite this, there is
no consensus metric by which improvement in these symptoms following shunting is
measured. Numerous studies either measuring outcomes or attempting to predict which
patients are most likely to respond to shunting have used a vast number of different
clinical scales to assess pre- and post-shunting symptom severity. These studies have also
employed a variety of inclusion criteria as a result of the absence of a single diagnostic
marker for iNPH other than response to shunting. As a result, comparing outcome
measures across studies is complicated, requiring careful attention be paid to the clinical
scales used in each study, the inclusion criteria employed by each study, and each study’s
threshold for scoring an outcome as a positive response to shunting.

In the sections that follow, I will first describe some of the types of clinical scales

24

encountered in the literature on iNPH. I will then discuss outcomes as reported in the
literature. An accompanying evidentiary table will outline which scales were used by
selected studies, each study’s inclusion criteria, and the criteria by which each study
scored an outcome as a positive response to shunting.

Outcomes – Scales and Rating Systems
Ordinal Scales
Ordinal scales, in which a patient’s symptoms are assigned a ranking according to their
severity, were amongst the first rating systems used in the evaluation of treatment
outcomes in iNPH. The symptom severity score in these scales is assigned based on the
evaluating clinician’s assessment of the patient. One of the oldest rating systems still in
use is the scale devised by Stein and Langfitt (3). This scale assigns a patient’s overall
symptomatology a score between 0 (no deficit) and 4 (patient requires full custodial
care). The clinical scale devised by Black (4) is similar to the Stein-Langfitt scale, as it
scores the patient’s overall symptomatology without distinguishing between specific
symptoms. Unlike the Stein-Langfitt scale, which enables the comparison of pre- and
postsurgical scores, the Black scale directly rates a patient’s response to treatment; a
grade of “poor”, “transient”, “fair”, “good”, or “excellent” is assigned based on the extent
and duration of improvement seen in a patient with iNPH’s symptoms following
shunting.

Ordinal scales that evaluate each symptom of iNPH separately have also been used
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(88,89,90,91,92,94). Though the criteria for specific rankings of symptom severity differ
from scale to scale, they all require individual scoring of at least gait disturbance,
cognitive impairment, and urinary incontinence. These specific symptoms scores are then
summed to provide a final iNPH score. As with the Stien-Langfitt, and Black scales, the
symptom scores are determined by the judgment of the assessing physician.

These scales are easy to employ and provide a general picture of the severity of a
patient’s disease. They are widely used and are the most common outcome assessment
tool encountered in the iNPH literature. A major disadvantage of these scales, however, is
that they are supported by few objective measures and rely heavily on the assessing
clinician’s judgment. To address this, the creators of one scale demonstrated significant
interrater reliability (κ = 0.76 – 0.85) when comparing a small number of expert raters,
though they cautioned that physicians less familiar with the treatment of iNPH would
likely need additional training before employing their scale (94). As such, there are
questions regarding the external validity of studies relying solely on ordinal scales to
assess patient outcome (100).

Improvement Indices
To facilitate more direct assessment of outcomes, at least two different improvement
indices have been proposed. Both begin with the scoring of either symptom severity or
improvement on an ordinal scale. The Krauss Improvement Index (85) scores symptom
improvement following shunting as 0 (no improvement), 1 (fair or good improvement),

or 2 (excellent improvement). The sum of these improvement scores is then divided by
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the two times the number of cardinal symptoms present prior to shunting. The end result
is a number between 0 and 1, with 0 indicating no improvement in any symptom, and 1
indicating excellent improvement in all symptoms. The NPH Recovery Rate, proposed by
Kiefer, et al. (89), begins with the calculation of pre- and post-surgical ordinal scale
ranking comprised of the sum of individual symptom scores. The NPH Recovery Rate is
then calculated by subtracting the pre- and postsurgical ordinal scores, dividing the result
by the presurgical score, and finally multiplying by ten - the larger the resulting NPH
Recovery Rate, the more significant the improvement in the patient’s symptoms.

Though these indices allow investigators to present the extent of a patient’s improvement
with a single number, they do not provide any information that is not available prior to
their calculation. In the case of the Krauss Improvement Index, outcome assessment can
be made from the ordinal outcomes score assigned to each symptom. The difference
between the pre- and postoperative ordinal scores in the numerator of the NPH Recovery
Rate also allows for assessment of outcome without any further calculation. Additionally,
these indices are limited by the reliability of the ordinal scales on which they are based.

Validated Measures
Other studies have assessed functional outcome or symptom severity using scales
validated in diseases other than iNPH. The Barthels ADL Index and Modified Rankin
Scale, both validated in the assessment of patients recovering from stroke, have been
used to gauge overall functional status in patients with iNPH (28,86,87,93,99). Many

studies have evaluated the cognitive symptoms of iNPH using the Mini Mental State
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Exam, which was validated as a screening test for dementia in elderly patients
(8,28,84,86,87,94,95). Numerous other psychometric tests have also been employed to
allow for more precise identification of a patient’s cognitive dysfunction (12). Likewise,
symptom specific tests for gait disturbance, such as the timed-up-and-go test, and urinary
incontinence, such as the International Consultation on Incontinence Questionnaire –
Short Form, have been used to evaluate the severity of those symptoms in iNPH
(28,94,95).

The use of validated tests addresses some of the limitations of iNPH-specific ordinal
scales, such as uncertain external validity. It should be noted, however, that, as these
scales were validated for the evaluation of diseases other than iNPH, their
generalizability needs to be examined. For example, the frontal-subcortical dysfunction
that is characteristic of the cognitive impairment in iNPH may not be detected by the
Mini Mental State Exam, which was validated for the assessment of Alzheimer’s type,
cortical dementia (101).

Continuous Scales
Recently, Hellstrom, et al. proposed a continuous iNPH rating scale based on a
combination of ordinal and objective assessments of gait, neuropsychology, balance, and
continence (102). Each symptom is scored from 0-100, with a score of 100 corresponding
to the performance observed in an age-matched healthy population. The gait and
neuropsychologic scores are the average of scores arising from both ordinal ranking and

objective assessment of symptom severity. For example, the final gait score is the
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average of three separate scores, each ranging from 0-100: an ordinal ranking, the
number of steps required to walk 10m, and the time in seconds required to walk 10m. The
balance and continence scores are provided by ordinal scales alone. The final iNPH score
is the mean of the symptom scores, provided by the equation [(2xgait) + (neuropsch) +
(balance) + (continence)]/5(or number of scores available). It should be noted that the
gait score is given twice the weight of the other symptom scores, and that the
denominator will change depending on the number of symptoms assessed at the time of
testing. The creators of this scale further recommend a minimum improvement of 5
points in the overall iNPH score as indicative of a response to shunting.

This scale attempts to address some of the limitations inherent in simple ordinal scales
through the inclusion of objective criteria for assessing gait and neuropsychologic
functioning. Hellstrom and colleagues also assert that their scale is calibrated such that a
score of 100 represents the performance of a healthy individual and lower scores provide
an empiric basis for comparison of iNPH scores between patients – for example, a score
of 50 corresponds to the 50th percentile of symptom severity. A significant limitation of
this scale, however, is that it takes significantly longer to administer – 30 to 40 minutes
total – compared to assessment with an ordinal scale. Additionally, two of its
components, balance and continence, are rated by ordinal scales alone. Though these
were shown to correlate significantly with the gait and neuropsychologic scores, they are
still limited by the reliability of the scales on which they are based.

Outcomes – Results
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Reported outcomes have varied widely. The most recent international guidelines quote an
overall shunt response rate between 30-96% (12). In formulating their most recent
guidelines, the Japanese Neurosurgical Society encountered 3-6 month improvement
rates following shunting of 64-96%, 1-year improvement rates of 41-95%, and 3-5 year
improvement rates of 28-91% in their review of the literature (13). A more recent review
of the literature found that in all studies of iNPH outcomes published since 2006,
improvement rates at 3 months, 1 year, and greater than 3 years were 81%, 82%, and
73%, respectively (16).

Improvement rates also vary between elements of the iNPH symptom triad. Gait is the
most likely symptom to improve, with response rates in cognitive impairment and urinary
incontinence both highly variable depending on the scales used to assess recovery.
Overall response rates for the symptoms have been reported between 58-90%, 29-80%,
and 20-82.5%, respectively (13).

The most recent data indicate that many patients’ symptoms will demonstrate long lasting
improvement following shunting for iNPH. A comparison of reviews of outcomes in
patients who had shunts implanted for the treatment of iNPH demonstrates a trend toward
better long term symptom improvement over the past 13 years; a 2001 review found that
29% of patients experienced “prolonged or significant improvement” (103), while a 2013
review reported that 73% of patients showed some improvement at 3 years or longer
following surgery (16). One recent study investigating long-term symptom improvement

found that 90% of patients will report some improvement in at least one symptom at 5
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years following shunting, and 87% will continue to report improvement at 7 years (95).
Another study reported an average Krauss Improvement Index of 0.70 at an average
follow-up of 80.9 months after shunt surgery (97).

Complication rates related to shunts in patients with iNPH have historically been high,
with early series quoting complication rates as high as 35%, including an 8% mortality
rate (4). A recent review showed that, since 2006, the overall complication rate of 21.4%,
with a 0.2% mortality rate. The most common complication found by this review was
need for later shunt revision, which accounted for 61% of all reported complications. The
remaining complications were subdural hematoma, intracerebral hemorrhage, and shunt
infection, which accounted for 20%, 1%, and 18% of all complications, respectively (16).

Previous guidelines have emphasized the importance of weighing an individual’s riskbenefit ratio when considering a patient with suspected iNPH for shunt surgery (10). To
examine this, a computer model, using data acquired through a review of the literature
current to 2005, ran a Monte Carlo simulation over a wide range of risk and benefit
parameters. Their model case was a 65 year-old with suspected iNPH and mild to
moderate Alzheimer’s type dementia. The simulation ran 1000 trials with 1000 patients
each. The resulting data indicated that the complication rate would have to exceed 50%
before liberal shunt implantation would cause more harm than benefit as measured by
QALYs gained in the trial’s model population (104).
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Review - Conclusion
The comparison of studies investigating normal pressure hydrocephalus is complicated
by an absence of both a consistently applied set of diagnostic criteria and a consensus
means of measuring patient outcomes following shunt surgery. Despite this, the most
recent data indicates that a majority of patients with iNPH will experience potentially

long-term improvement of at least one aspect of their syndrome with shunt implantation.

Though careful patient selection should remain at the center of all surgical decisionmaking, the trends over the past decade with respect to shunt surgery in patients with
suspected iNPH have been of decreasing risk and increasing effectiveness. It is likely that
more patients with suspected iNPH would benefit from earlier shunting (104), and that
even patients with significant medical and neurologic comorbidity would experience
some benefit from CSF diversion (90,91,98,99).

Patient-Reported Outcomes in iNPH
Introduction
In the absence of consensus diagnostic criteria or methods of measuring outcomes, the
effectiveness of CSF diversion via surgical implantation of a shunt remains difficult to
assess with certainty. Despite this, as demonstrated by the preceding review of the
literature, the preponderance of evidence indicates that a significant number of patients
will experience at least some improvement of their symptoms following shunt surgery.
Though numerous clinical scoring systems have provided this heterogeneous body of

data, one significant end-point that is seldom reported is the patient-reported outcome
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(PRO).

PROs are widely used in the clinical literature,
often in conditions in which there is no easily
quantified primary end-point (106). Given the

Table 1
Patient Characteristics at Presentation
77.76 years
Average age
Sex

lack of consensus metrics for measuring

Female
Male

9 (42.86%)
12 (57.14)

objective improvement in the iNPH, PROs
could provide insight into the effectiveness of treatment for this disorder.

This analysis examines the experience of patients treated for iNPH at our institution, and
will report PROs pertaining to symptom improvement or deterioration following shunt
surgery. The primary goal of this analysis is to compare outcomes provided by PROs
with the most recent outcomes data reported by reviews of the literature employing
traditional clinical scales such as those described in the preceding review (13,16). A
secondary objective of this analysis will be to see if there are patient characteristics that
significantly correspond to a pattern of response as recorded from PROs.

Methods
Patients

I conducted a retrospective evaluation of
patients treated for iNPH with surgical

Symptoms at presentation
Gait
Urinary

implantation of a CSF diverting shunt
between January 2012 and January 2014. All
patients’ surgeries were performed by the
same provider. The diagnosis of iNPH was

three cardinal symptoms of gait disturbance,

18 (85.71)

Full triad

17 (80.95)

5 (23.81)

Duration of symptoms
< 12 months

9 (42.86)

>12 months

12 (57.14)

Cardiovascular comorbidities
Hypertension
17 (80.95)
Diabetes mellitus
4 (19.05)
Coronary artery disease

6 (28.57)

Peripheral vascular
disease
Hyperlipidemia
Any

2 (9.52)

and imaging confirmed communicating

patients with at least one month of follow-up

Cognitive

Not performed

urinary incontinence, or cognitive impairment,

ventriculomegaly of unknown etiology. All

21 (100)
19 (90.48)

Response to trial CSF diversion
Improved
15 (71.43)
Not improved
1 (4.76)

based on onset of disease in adulthood,
progressive worsening of at least one of the
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Neurologic comorbidities
Dementia

9 (42.86)
20 (95.24)
7 (33.33)

Parkinson’s disease

4 (19.05)

History of seizure
disorder
Tremor
Any

2 (9.52)

and documented response to direct
questioning about their pre- and post-

1 (4.76)
9 (42.86)

operative symptom severity were included in the study. In total, 21 patients were
included in the final
analysis. Relevant patient data can be found in Table 1.

Evaluation
All patient data were obtained through a search of each patient’s electronic medical
record.
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Patients were evaluated in clinic by the same provider who would later perform shunt
surgery. The clinical assessment of the physician with respect to severity of the three
cardinal symptoms of gait disturbance, urinary incontinence, and cognitive impairment
were recorded in each visit note. Additionally, the patient’s assessment of their
symptomatology on direct questions about each symptom was recorded in each note.
When present, the assessment of the patient’s primary health aide (e.g. spouse, visiting
nurse) was also recorded. For the purposes of this analysis, a patient was considered to
have a symptom at presentation if they endorsed progression of a cardinal symptom over
time to the point where it had impacted their quality of life.

Each patient underwent implantation of a right ventriculoperitoneal shunt using a
MIETHKE proGAV adjustable, gravitational shunt system. The hospital course and 30day post-operative period of each patient were assessed for complications. Major
complications were considered to be those that led to reoperation, hospital readmission,
or deficit which would potentially negate any positive impact conferred by shunting at
last follow-up. Minor complications included transient deficits and over- or underdrainage from the shunt system correctable by adjustment of the shunt’s settings.

At follow-up, all patients were directly asked to assess their current symptom severity
relative to their pre-operative condition. Again, when applicable, the assessments of
primary health aides were also recorded. In cases where both the patient’s and a health
aide’s assessments were available, a patient was only scored as improved if both the
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patient and the aide considered the patient improved post-operatively. For the purposes of
this analysis, only patients who continued to self-report improvement in a symptom
domain at their last follow-up were scored as improved.

Based on the pattern of response, patients were divided into a complete-response cohort,
for whom all symptom domains were improved by PROs at last follow-up, and an
incomplete-response cohort. Significant difference in categorical data between the
complete-response cohort and the incomplete-response cohort was examined using a twotailed Fisher’s exact test. As an F-test did not reveal significant difference in variance
between the two cohorts, significant difference in continuous data was examined using a
standard independent-samples t-test. Significant difference in the rate of response
between symptoms was also investigated using a two-tailed Fisher’s exact test.

Estimates for frequency of response to shunting reported in the most recent systematic
review available for each symptom (13,16) were chosen to represent historical outcomes
as measured by traditional clinical scales. Comparison of our cohort data and this
historical data was performed using chi-squared analysis.

3.3 Results
All patients reported improvement in at least one symptom domain at last follow-up, and
all but five patients reported improvement in all three symptom domains. Of the five
patients who experienced no improvement or worsening of at least one patient domain,
one patient experienced a worsening of their gait disturbance, one patient experienced no
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change in their cognitive impairment, two patients experienced no improvement in their

urinary incontinence, and one patient failed to respond in both the urinary and cognitive
domains. A summary of the overall pattern of response is available in Table 2.

Table 2
Response by Symptoms
Present pre-operatively
Improved at last follow-up
Symptom
Gait
Urinary
Cognitive
Full triad

21
19
18
17

20 (95.24%)
16 (84.21)
16 (88.89)
13 (76.47)

There was not a statistically significant difference in response to shunting between
patterns of symptomatology at patient presentation.

A comparison of the complete-response cohort to the incomplete-response cohort can be
found in Table 3.

37
Table 3
Patient Characteristics by Complete or Incomplete Response to Shunting
Complete Response (n = 16)
Incomplete Response (n = 5)
76
83.4
Average Age*
Sex
Female
7 (43.75%)
2 (40%)
Male
9 (56.25)
3 (60)
Symptoms at presentation
Gait
16 (100)
5 (100)
Urinary
15 (93.75)
4 (80)
Cognitive
13 (81.25)
5 (100)
Response to trial CSF Diversion
Improved
11 (68.75)
4 (80)
Not improved
1 (6.25)
0 (0)
Not performed
4 (25)
1 (20)
Duration of symptoms
< 12 months
6 (37.5)
3 (60)
> 12 months
10 (62.5)
4 (40)
Cardiovascular comorbidities
Hypertension
13 (81.25)
4 (80)
Diabetes mellitus
3 (18.75)
1 (20)
Coronary artery disease
4 (25)
2 (40)
Peripheral vascular
1 (12.5)
0 (0)
disease
Hyperlipidemia
7 (43.75)
2 (40)
Any
15 (93.75)
5 (100)
Neurologic comorbidities
Dementia
5 (31.25)
2 (40)
Parkinson’s disease*
1 (6.25)
3 (60)
Any
5 (31.25)
4 (80)
Complications
Major
2 (12.5)
1 (20)
Minor
4 (25)
1 (20)
Total
6(37.5)
2 (40)
* p-value < 0.05
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The incomplete-response cohort demonstrated significantly higher average age and
prevalence of Parkinson’s disease than the complete-response cohort. No other
significant differences in patient characteristics were demonstrated. With respect to rate
of improvement in any symptom domain, a significant difference was seen between our
PROs and historical outcomes based on clinical scales. Otherwise, no significant
difference was found between our PROs and clinically assessed historical data. These
findings are summarized in table 4.
Table 4
Response Compared to Historical Data
% improved - PRO
% improved - historical
Symptom
Gait
95.24
90
Urinary
84.21
82.5
Cognitive
88.89
80
Any*
100
82
*p-value < 0.05

Discussion
Patient Selection Rationale and Patient Characteristics
As there is no consensus means of securing a diagnosis of iNPH except for a witnessed
response to shunt implantation, and as current evidence suggests that more patients may
benefit from earlier shunting, we applied a liberal set of diagnostic criteria, requiring only
onset of disease in adulthood, gradual worsening of one of the cardinal symptoms of
iNPH, and ventriculomegaly of unknown etiology on neuroimaging. Despite this, our
patient population had a higher prevalence of the full clinical triad than what has been
reported in previous reviews (10, 13), and most met the criteria for a diagnosis of
“probable iNPH” as outlined by Mori et al (13).
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This inconsistency between our lenient diagnostic criteria and our patient population is
likely a result of bias introduced by the referral pattern of our clinic. It is possible that
referring physicians did not suspect iNPH until many features of the disease were present.

Though the rate of cardiovascular comorbidity was very high in our patient population,
each disease-specific prevalence was not significantly higher than those demonstrated in
age-matched population studies (107). This was not the case with neurologic
comorbidities; the rates of dementia and Parkinson’s disease in our patient population
were both approximately five-times greater than those reported for age-matched cohorts
in large epidemiologic studies (108,109). These higher rates of neurologic comorbidity
may be consistent with previously reported findings of extremely high rates of
histopathologic evidence of neurodegenerative disease in patients with iNPH (21,22).

Our patient population largely resembled the population of previous studies of iNPH in
so far as they were elderly, gait was the most common symptom at presentation, and the
neurologic disease burden was higher than that seen in the general population. It differed
from previous iNPH study populations primarily in the frequency with which patients
presented with the full clinical triad of gait disturbance, urinary incontinence, and
cognitive impairment.

Comparison of Patient-Reported Outcomes to Historical Outcomes

40

The PROs of this study were responses to a direct question asking the patient to compare
their pre- and post-surgical symptom severity. In total, our findings are largely consistent
with the historical clinical outcomes data; gait is the most likely symptom to show
improvement, while cognitive and urinary symptoms are less responsive. Overall, all
three symptoms domains demonstrated a response rate greater than 80% following
implantation of a shunt.

Two factors likely contributed to the significant difference in the rate of improvement in
any (i.e. at least one) symptom domain demonstrated between this study and the
historical data despite the absence of a significant difference in the rate of response for
each individual symptom domain. First, it is possible that the insignificant differences in
the rate of improvement observed between our data and the historical data with respect to
each symptom reached significance when the datasets were combined to tabulate the
outcome in the “any” domain. It is also likely that difference in method between the
reviews from which the historical data was collected contributed to this result (13,16).
Unfortunately, there has not been a single systematic review examining the response of
all individual symptoms, which necessitated the compiling of this data from various
sources. Likewise, there has been no review on the rate of response to shunting by
symptoms at presentation; as such, there was no reliable data available on the historical
rate of improvement in the symptoms of patients presenting with the full triad. This
would have been useful, as our cohort included a large number of patients with all three
cardinal symptoms.
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In the absence of a gold-standard metric for assessing outcomes in iNPH, this study
demonstrates that PROs obtained from a typical iNPH patient population produce largely
similar data on the effectiveness of shunting when compared to the various clinical scales
that have been historically employed in the literature. The differences that are observed
demonstrate higher rates of symptom improvement, though this is only significant when
outcomes from all symptom domains are summed. A larger, prospective study comparing
PROs and assessment using a clinical scale would be useful in determining if PROs
actually lead to higher reported rates of symptom improvement. If such a difference were
to be confirmed, further study would be needed to determine the reasons underlying the
patient perception of improvement in the absence of improvement on clinical grading
scales.

Comparison of Complete-Response Cohort and Incomplete-Response Cohort
Significant differences in average age and the prevalence of Parkinson’s disease were
demonstrated between the complete-response cohort and the incomplete-response cohort.
The average age of patients in the incomplete-response cohort was more than seven years
greater than the average age in the complete-response cohort, and of the four patients in
our total patient population with Parkinson’s disease, three failed to achieve improvement
in all symptom domains. Of note, the symptoms that did not improve in the patients with
Parkinson’s disease, urinary incontinence and cognitive impairment, are also known to
occur in the course of that illness. As such, it is possible that the lack of response to
shunting in these patients is the result of their underlying comorbid condition.

Significantly, however, these patients still reported experiencing improvement of their
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gait dysfunction. This supports previously reported data that even patients with suspected
iNPH who also have significant neurologic comorbidity can derive some benefit from
shunt implantation (90,91,98,99).

That there is an association between age, comorbid illnesses, and response to shunt
surgery in iNPH underscores the fact that careful patient selection based on overall
fitness and ability to tolerate surgery is still crucial to obtaining good outcomes. The
presence of improvement in at least one symptom in all of our patients, however,
indicates that CSF diversion via surgical implantation of a shunt can provide some relief
from the symptoms of iNPH even in otherwise significantly ill patients.

Limitations
Limitations of this study include retrospective design, absence of the application of
clinical grading scale against which to directly compare PROs in the evaluation of our
subjects, and small sample size.

Conclusion
Using patient-reported outcomes to assess patients having undergone shunt surgery for
the treatment of iNPH leads to the reporting of similar rates of improvement when
compared to historical data obtained through the application of clinical scales. Further
study is needed to investigate whether or not PROs lead to higher rates of reported
improvement relative to clinical scales, and to elucidate what factors contribute to a

patient’s perception of their own improvement. Until a consensus metric for evaluating
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outcomes in iNPH is established, however, PROs should be considered a viable method
of assessing the effectiveness of shunt surgery for the treatment of iNPH.
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Study
Stein and
Langfitt (1974)

Study
Population
33 patients with
iNPH, 10 with
secondary NPH

Black (1980)

62 patients with
iNPH

Raftopoulos, et
al.
(1996)

23 patients with
iNPH

Appendix 1 – Evidentiary Table
Clinical Scales /Tests
Outcome
Used
Assessment
Progressive Dementia
-Stein-Langfitt: Patients
Significant
less than 2 years in
rated on a scale from 0 –
improvement
duration, confirmed
IV based on overall
defined as at least
ventriculomegaly,
symptom severity (0 = no one point increase
normal opening
symptoms, IV = full
in Stein-Langfitt
pressure, absence of
custodial care necessary)
functional score
obstructive etiology
Variable, with
-Black: Patient outcome
Improvement
minimum criteria of
scored from “Poor” to
defined as:
ventriculomegaly,
“Excellent” based on
Excellent, Good,
dementia and/or gait
combination of functional Fair, or Transient
disturbances, and
and neurologic outcomes. outcome on Black
-Stein-Langfitt
normal opening
Scale or: one point
pressure
increase in SteinLangfitt score
1) Gait disturbances or
Gait assessed by
Results divided
dementia; 2) Imaging
equations requiring
into great
confirmed
number of steps, time
improvement,
ventriculomegaly; 3) a
required, and whether or
moderate
mean intraventricular
not assistance is required
improvement, no
pressure or a lumbar
to walk 10m. Cognition
change, moderate
pressure <20 cm H2O;
assessed using a battery of deterioration, or
4) no identifiable cause psychometric tests
severe deterioration
for hydrocephalus; 5)
including the MMSE.
based on an
the ability to walk
equation
within one year before
comparing pre- and
the intracranial pressure
post-procedure
monitoring; 6) the
results for each
presence of intracranial
symptom
pressure waves with an
assessment test.
amplitude >9 mm Hg
Shunt response
defined as great or
Inclusion Criteria

Follow-up

Results

6-30 months,
mean 18
months

24% of patients with
INPH showed significant
improvement

9 weeks to 75
months, mean
36.5 months

46.8% improved by Black
scale definition, 33%
improved by SteinLangfitt definition

9 days, 2
months, with
subsequent
annual
follow-up

91% of patients continued
to show improvement in
at least on symptom at
last follow-up
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moderate
improvement.
Krauss, et al.
(1996)

41 patients with
iNPH

Gait disturbance,
imaging confirmed
ventriculomegaly,
improvement of gait
disturbances with CSF
removal

Boon, et al.
(1998)

85 patients with
iNPH, 11 with
secondary NPH

Malm, et al.
(2000)

42 patients with
iNPH

Gradually developing
gait disturbance
effecting both legs,
mild to moderate
cognitive impairment
without aphasia, mRS
of at least 2, imagingconfirmed
communicating
hydrocephalus,
Imaging confirmed
ventriculomegaly
without significant
leucoaraiosis, gait
disturbances

Gait, cognitive, and
urinary symptoms scored
from 0-3 (0 = no
symptoms, 3 = severe
symptoms). Improvement
in each symptom
following shunting scored
from 0-2 (0 = no
improvement, 2 =
significant improvement)
-Krauss Improvement
Index (KII): (sum of
improvement scores)/2n,
where “n” is the number
of cardinal symptoms
manifest at presentation
NPH scale (sum of
dementia and gait scales),
Modified Mini Mental
State Exam, mRS

Shunt response was
defined as a KII >
0 at last follow-up.

3-59 months,
average
follow-up 16
months

90% of patients with gait
disturbance, 88% of
patients with cognitive
impairment, and 76% of
patients with urinary
symptoms showed
improvement at last
follow-up.

Categorized as
none, moderate,
marked, or
excellent based on
% improvement in
NPH score or
improvement in
mRS

1, 3, 6, 9, and
12 months

MMSE, Barthel Index,
video recording of
ambulation

Response to
shunting defined as
MMSE score
greater than or
equal to 25 or an
increase of at least
two points in
MMSE score or

3, 9, 18, and
36 months

74% of patients implanted
with low-pressure shunts,
and 53% of patients
implanted with medium
high-pressure shunts
showed some
improvement, with the
mRS definition providing
more statistically
significant findings
Mental status and gait
responded to shunting in
69% and 67.5% of
patients at 3 months, and
28% and 26% at 36
months, respectively. 75%
of patients were living
independently at 3
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Mori (2001)

120 patients
with iNPH

Imaging confirmed
ventriculomegaly and
presence of full clinical
triad of gait
disturbances, cognitive
impairment, and urinary
incontinence

iNPH grading scale
established by the
Research Committee on
Intractable Hydrocephalus
(Japan) – calculated from
sum score from 0-4 for
each cardinal symptom (0
= no symptoms, 4 = worst
symptoms)

Kiefer, et al.
(2002)

91 patients with
iNPH

Variable; based on
clinical presentation
and CSF dynamic
parameters

Poca, et al.
(2004)

43 patients with
iNPH

Imaging confirmed
ventriculomegaly, and
at least one of the
following symptoms:
gait disturbance,
cognitive deficits,
treatment refractory
Parkinsonism, or
sphincter incontinence.

-Kiefer Index (KI): gait,
cognitive, and urinary
symptoms scored from 06, headache from 0-4, and
dizziness from 0-2. Scores
summed to provide Kiefer
index (high = more
symptomatic disease)
-Recovery Index (RI):
[(preop KI – postop KI) x
10]/(preop KI)
iNPH scale calculated
from sum of score from 15 for each cardinal
symptom (1 = severe
symptoms, 5 = no
symptoms). SteinLangfitt. Activities of
Daily Living Scale.
Informant Questionnaire

clinician
assessment of
improved
ambulation.
Independent living
defined as Barthel
Index > 65
Response to
shunting defined as
improvement by at
least on point on
iNPH scale

Response to
shunting defined
as:
-Non-responders
(RI 0-1)
-Moderate response
(RI 2-4)
-Good response (RI
5-7)
-Very good
response (RI > 7)
Improvement
categorized as:
-None
-Mild
(improvement of
one point on NPH
scale)
-Moderate
(improvement of

months, versus 28 % at 36
months.

3 and 36
months

6 to 60
months,
average
follow-up 26
months

6 months

80% of patients showed
improvement at 3 months,
and 73.3% had sustained
improvement at 36
months. Gait symptoms
were more likely to
improve than dementia or
urinary symptoms (79.2%
v. 20.8%, respectively, at
3 months)
>65% of patients had
good or very good
recovery at last follow-up.
88% of patients were
shunt responders.

86% of patients showed
some improvement. Gait,
incontinence, and
cognitive symptoms
experienced improvement
rates of 85%, 86%, and
40%, respectively.
Neuropsychological
testing and MMSE did not
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on Cognitive Decline in
the Elderly

two or more points
on NPH scale)

Poca, et al.
(2005)

12 patients with
iNPH and
negative
prognostic
factors

Same as Poca, et
al.(2004), plus age >
65, symptom duration >
12 months, cortical
atrophy, and MMSE <
24

Same as above

Improvement
categorized as:
-None
-Mild
(improvement of
one point on scale)
-Moderate
(improvement of
two or more points
on scale)

6 months

McGirt, et al.
(2005)

132 patients
with iNPH

Confirmed
ventriculomegaly, at
least two of the
symptoms of gait
disturbance, cognitive
deficit, or urinary
incontinence, no
obvious etiology of
their hydrocephalus, Aor B-waves on
continuous CSF
pressure monitoring,
and improvement with
3-day lumbar drain trial

MMSE, patient or care
provider reported quality
of life

1, 3, and 6
months with
subsequent
annual
follow-up,
mean followup of 18
months.

Eide, et al.
(2006)

39 patients with
iNPH

Not specified

iNPH scale calculated
from sum of score from 15 for each cardinal
symptom (1 = severe
symptoms, 5 = no

Improvement in
symptoms assessed
based on patientreported
improvement.
Cognitive
symptoms
additionally
considered
improved with > 3
point increase in
MMSE. Response
to shunting scored
as improvement in
at least one
symptom.
Improvement
categorized as:
-Very Significant
(> 5 point
improvement on

12 months

show statistically
significant difference preand post- procedure.
92% of patients
experienced some
improvement. Gait,
incontinence, and
cognitive symptoms
experienced improvement
rates of 92%, 92%, and
33%, respectively.
Neuropsychological
testing and MMSE did not
show statistically
significant difference preand post- procedure.
75% of patients showed
improvement in at least
one symptom and 46%
had improvement in all of
their symptoms at the
study’s conclusion. Gait
disturbance was the most
likely symptom to
improve

69% of patients showed
some improvement at 12
months. 31% showed very
significant improvement,
and 15% showed
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symptoms).

iNPH scale)
-Significant (3-4
point improvement
on iNPH scale
-Slight
Improvement (1-2
point improvement
on iNPH scale)
-Non-responders
Authors report %
change in scores of
pre- and postoperative tests

significant improvement.

Kahlon, et al.
(2007)

46 patients with
iNPH, 8 with
secondary NPH

Imaging confirmed
ventriculomegaly, at
least one of symptoms
of gait disturbance,
cognitive impairment,
or urinary incontinence,
and either positive
lumbar infusion test of
CSF tap test

Walk time, step number
reaction time, memory,
identical forms tests, and
Barthel index

6 months (all
patients) and
5 years (23
patients)

Kubo, et al.
(2007)

38 patient with
iNPH evaluated
to validate new
iNPH scale. 14
eventually
shunted.

iNPH grading scale
calculated as sum of score
from 0-4 for each cardinal
symptom (0 = no
symptoms, 4 = worst
symptoms). MMSE,
Frontal Assessment
Battery, Gait Status Scale,
Timed up-and-go,
International Consultation
on Incontinence
Questionnaire – Short
Form

Quantified change
in iNPH scale
presented in results

1 to 12
months

Pujari, et al.
(2008)

55 patients with
iNPH

Age > 60 years, at least
one of the symptoms of
gait disturbance,
cognitive impairment,
or urinary incontinence,
imaging confirmed
ventriculomegaly,
absence of known
etiology of
hydrocephalus, and
normal opening
pressure on lumbar
puncture. Decision to
shunt based on
individual surgeon’s
opinion.
See: McGirt (2005)

MMSE, Tinetti gait score,
patient or care provider

See: McGirt (2005)

1, 3, and 6
months, with

More than 80% of
patients showed objective
improvement and 96%
reported subjective
improvement at six
months. 43% of patients
showed some objective
improvement and 56%
reported subjective
improvement at 5 years
79% of shunted patients
showed at least one point
of improvement on the
iNPH grading scale

71% of patients reported
improvement in all
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reported quality of life

Kiefer, et al.
(2010)

75 patients with
iNPH, 50
patients with
“non-iNPH”

Presentation with at
least two of the
symptoms of gait
disturbance, cognitive
impairment, or urinary
incontinence, and
imaging confirmed
ventriculomegaly

Mirzayan, et al.
(2010)

51 patients with
iNPH

Presence of gait
disturbance, imaging
confirmed
ventriculomegaly with
flattening of the
parasagittal,
frontoparietal sulci, and
improvement of gait
with CSF drainage

Hashimoto, et
al.
(2010)

100 patients
with iNPH

Age between 60 and 85,
at least one of the
symptoms of gait
disturbance, cognitive

-Kiefer Index (KI)
-Recover Index (RI)
-Comorbidity Index
(CMI): between 1-3
points assigned for
comorbidities in each of
the following categories:
peripheral vascular
disease/vascular risk
factors, cerebrovascular
disease,
electrical/structural heart
disease, and other
neurologic disease
Krauss Improvement
Index

Response to
shunting defined at
RI > 3 at final
follow-up

mRS, Kubo’s iNPH
grading scale, Timed upand-go, MMSE

Response to
shunting defined as
at least one point of
improvement on

KII reported in
results

annual
follow-up
thereafter.
Patients
followed for a
minimum of
3 years,
maximum of
7 years.
2-3 months,
12 months,
then annually.
Average
follow-up of
5.1 years

symptoms at 3 years
following shunt surgery.
80% of patients still
followed at 7 years
continued to report
improvement of all
symptoms relative to presurgical baseline.

Divided into
“short term”
and “long
term” followup. -Short
term: avg.
18.8 months.
-Long term:
avg. 80.9
months
12 months

Average long-term KII
for gait, cognitive, and
urinary symptoms were
.75, .67, and .67,
respectively.

iNPH patients with CMI
0-3 had >80% response
rate. When controlled for
age and CMI, there was
no statistically significant
difference in the response
rate between iNPH and
non-iNPH. Patients with
iNPH were ten-fold more
likely to have an older age
and a higher CMI at
presentation than patients
with non-iNPH.

80% of patients
responded to shunting
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Tisell, et al.
(2011)

14 patients with
iNPH and
Binswanger’s
disease

Klinge, et al.
(2012)

115 patients
with iNPH

impairment, or urinary
incontinence, imaging
confirmed
ventriculomegaly,
absence of known
etiology of
hydrocephalus, and
opening pressure <
20cm H2O on LP
Confirmed
ventriculomegaly,
“symptoms and signs of
iNPH”, and Wahlund
score 2 or 3 white
matter changes

Split patients into
“typical” or
“questionable” iNPH.
-Typlical: 1)Gradual
onset of gait
disturbance effecting
tandem walk, turning,
and stride length; 2)
mild to moderate
(MMSE score greater
than or equal to 21)
cognitive impairment
presenting together with
or after presentation of
gait symptoms; 3) MRI

mRS at one year

Seven psychometric tests
(Bingley, Identical Forms,
Reaction Time, Grooved
Pegboard, RAVLT,
Tracks, Stroop Color
Naming) and six motor
tasks (time to sit upright
from lying down, time to
walk 10 m, time to climb
up and down six stairs,
no. of steps to turn 180,
no. of steps to walk 3 m
backwards)
mRS,
-Hellstrom’s iNPH scale:
The domains of gait
impairment, cognitive
ability, balance, and
urinary incontinence are
each given a score from
0-100 based on a
combination of ordinal
clinical scales or objective
tests unique to each
symptom. The iNPH
score is then calculated by
the equation
[2(gait)+(cognitive)+(bala

Response to
shunting measured
as change in mean
of motor and
psychometric tests

3 and 6
months

22% overall improvement
in aggregate average
scores for all 14 patients
at 6 months

Response to
shunting defined as
improvement in
mRS of at least one
point or
improvement of at
least 5 points on
Hellstrom’s iNPH
scale

12 months

64% and 84% of patients
were improved at one
year by mRS and
Hellstrom’s iNPH scale
criteria, respectively. 82%
of patients were living
independently at one year
compared to 53% before
surgery.
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Andren, et al.
(2014)

33 patients with
iNPH waiting
at least 6
months
between
diagnosis and
shunt surgery,
and 69 patients
waiting no
more than 3
months
between
diagnosis and
shunt surgery

findings of
quadriventricular
enlargement with little
or no leucoaraiosis.
-Questionable: 1)
atypical gait
disturbances; 2)
cognitive impairment
including aphasia,
apraxia, or agnosia, or
MMSE score < 21; 3)
MRI with
ventriculomegaly and
cortical atrophy, also
including either mild to
severe leucoaraiosis or
single area of infarct
“Possible” or
“probable” iNPH as per
criteria set forth in most
recent international
guidelines (10)

nce)+(urinary)]/5(or total
number of scores
available)

Hellstrom’s iNPH scale

Improvement of at
least 5 points on
Hellostrom’s iNPH
scale

3 months

Significant improvement
following shunting was
demonstrated in all
symptoms domains in
each group. There was a
significant difference in
the degree of
improvement between the
delayed shunting cohort
and the early shunting
cohort, with the early
shunting cohort having a
greater degree of
improvement in all
domains except for
incontinence and MMSE,
for which there was no
significant difference
between the groups.
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